BACKGROUND: GB virus C (GBV-C) coinfection is associated with reduced immune activation and a block in CD4(+) T-cell proliferation following interleukin-2 (IL-2) therapy in HIV-infected individuals. We examined peripheral blood mononuclear cells (PBMCs) from HIV-infected subjects with and without GBV-C viraemia to determine if GBV-C correlated with reactivation of latent HIV, T-cell proliferation or T-cell survival following in vitro activation with phytohaemagglutinin A and IL-2 (PHA/IL-2). METHODS: HIV-infected subjects whose HIV viral load was suppressed on combination antiretroviral therapy (cART) for >6 months were studied. PBMCs were cultured with and without PHA/IL-2 and monitored for HIV reactivation, proliferation and survival. GBV-C viraemia and in vitro replication were detected by real-time RT-PCR. HIV reactivation was determined by measuring HIV p24 antigen in culture supernatants. Proliferation was measured by counting viable cells and survival measured by flow cytometry. RESULTS: Of 49 HIV-infected individuals, 26 had GBV-C viraemia. Significantly less HIV reactivation and PBMC proliferation following in vitro activation with PHA/IL-2 was observed in samples from GBV-C viraemic subjects compared with non-viraemic controls. Following 5 weeks in culture, GBV-C replication was associated with preservation of CD4(+) and CD8(+) T-cells compared with non-viraemic controls. CONCLUSIONS: GBV-C appears to inhibit immune activation and IL-2 signalling pathways, which might contribute to a reduction in reactivation of latent HIV from cellular reservoirs. In addition, GBV-C viraemia was associated with a reduction in activation-induced T-cell death. GBV-C-associated T-cell effects could contribute to the observed protective effect of GBV-C coinfection in HIV-infected individuals.
BACKGROUND:GB virus C (GBV-C) coinfection is associated with reduced immune activation and a block in CD4(+) T-cell proliferation following interleukin-2 (IL-2) therapy in HIV-infected individuals. We examined peripheral blood mononuclear cells (PBMCs) from HIV-infected subjects with and without GBV-C viraemia to determine if GBV-C correlated with reactivation of latent HIV, T-cell proliferation or T-cell survival following in vitro activation with phytohaemagglutinin A and IL-2 (PHA/IL-2). METHODS:HIV-infected subjects whose HIV viral load was suppressed on combination antiretroviral therapy (cART) for >6 months were studied. PBMCs were cultured with and without PHA/IL-2 and monitored for HIV reactivation, proliferation and survival. GBV-C viraemia and in vitro replication were detected by real-time RT-PCR. HIV reactivation was determined by measuring HIV p24 antigen in culture supernatants. Proliferation was measured by counting viable cells and survival measured by flow cytometry. RESULTS: Of 49 HIV-infected individuals, 26 had GBV-C viraemia. Significantly less HIV reactivation and PBMC proliferation following in vitro activation with PHA/IL-2 was observed in samples from GBV-C viraemic subjects compared with non-viraemic controls. Following 5 weeks in culture, GBV-C replication was associated with preservation of CD4(+) and CD8(+) T-cells compared with non-viraemic controls. CONCLUSIONS:GBV-C appears to inhibit immune activation and IL-2 signalling pathways, which might contribute to a reduction in reactivation of latent HIV from cellular reservoirs. In addition, GBV-C viraemia was associated with a reduction in activation-induced T-cell death. GBV-C-associated T-cell effects could contribute to the observed protective effect of GBV-C coinfection in HIV-infected individuals.
Authors: D H Dockrell; A D Badley; A Algeciras-Schimnich; M Simpson; R Schut; D H Lynch; C V Paya Journal: AIDS Res Hum Retroviruses Date: 1999-11-20 Impact factor: 2.205
Authors: Frank Wolschendorf; Alexandra Duverger; Jennifer Jones; Frederic H Wagner; Jason Huff; William H Benjamin; Michael S Saag; Michael Niederweis; Olaf Kutsch Journal: J Virol Date: 2010-06-10 Impact factor: 5.103
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: J Xiang; S Wünschmann; D J Diekema; D Klinzman; K D Patrick; S L George; J T Stapleton Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: H L Tillmann; H Heiken; A Knapik-Botor; S Heringlake; J Ockenga; J C Wilber; B Goergen; J Detmer; M McMorrow; M Stoll; R E Schmidt; M P Manns Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks Journal: J Infect Dis Date: 2003-04-23 Impact factor: 5.226
Authors: Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton Journal: Br J Haematol Date: 2018-05-29 Impact factor: 6.998
Authors: Jack T Stapleton; Jeffrey A Martinson; Donna Klinzman; Jinhua Xiang; Seema N Desai; Alan Landay Journal: AIDS Date: 2013-07-17 Impact factor: 4.177
Authors: Cindy M Chang; Jack T Stapleton; Donna Klinzman; James H McLinden; Mark P Purdue; Hormuzd A Katki; Eric A Engels Journal: Cancer Res Date: 2014-08-12 Impact factor: 12.701
Authors: Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton Journal: Virology Date: 2012-05-16 Impact factor: 3.616
Authors: Marion C Lanteri; Farnaz Vahidnia; Sylvia Tan; Jack T Stapleton; Philip J Norris; John Heitman; Xutao Deng; Sheila M Keating; Don Brambilla; Michael P Busch; Brian Custer Journal: J Infect Dis Date: 2014-11-25 Impact factor: 5.226
Authors: James H McLinden; Jack T Stapleton; Donna Klinzman; Krishna K Murthy; Qing Chang; Thomas M Kaufman; Nirjal Bhattarai; Jinhua Xiang Journal: J Gen Virol Date: 2013-01-03 Impact factor: 3.891
Authors: Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Alan L Landay; Ernest T Chivero; Jack T Stapleton Journal: J Immunol Date: 2013-05-17 Impact factor: 5.422